Background
Dystonia is a syndrome characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Idiopathic cervical dystonia (CD; dystonia of the neck) is the most common form of dystonia [
1]. Dystonia has commonly been assumed to be a disorder of the dopaminergic system [
2]. Previous imaging studies in different types of dystonia have mostly shown normal radiotracer binding to striatal dopamine transporters (DAT) and normal or decreased binding to striatal dopamine D
2/3 receptors (D2/3 receptors) [
3,
4]. We recently showed normal striatal DAT binding but decreased D2/3 receptor binding in CD. We also showed a significant relationship between striatal DAT binding and jerks/tremor of the head, which is a common symptom in CD, and a significant and negative relationship between both striatal DAT and D2/3 receptor binding and depressive symptoms [
5].
Psychiatric symptoms, mainly depressive symptoms and anxiety, are very common in patients with dystonia with an estimated lifetime prevalence between 40 and 70% [
6] and are thought to be part of the dystonia phenotype [
6]. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging studies in patients with major depression mostly showed reduced serotonin transporter (SERT) binding [
7,
8]. Reduced SERT binding in depression is hypothesized to reflect decreased expression of SERTs. In line with this, postmortem studies in patients with major depressive disorder found reduced expression of SERTs in several brain regions including the midbrain [
9].
The role of serotonin in dystonia has not been studied with imaging or postmortem, but there are strong indications that alterations of the serotonergic system may indeed play a role. There have been many case reports of drug-induced dystonia after the use of selective serotonin reuptake inhibitors (SSRIs) [
10]. Furthermore, studies in patients with dopa-responsive dystonia and idiopathic adult-onset dystonia found decreased levels of serotonin metabolites, mainly 5-hydroxyindoleacetic acid (5-HIAA), in cerebrospinal fluid [
11,
12]. In the rare genetic syndrome of 5-HIAA deficiency, serotonin levels are low in the brain and patients suffer from dystonia [
13]. In addition, the role of serotonin in myoclonus pathophysiology gained more attention lately [
14], and approximately 50% of CD patients have myoclonus (jerks) or tremor of the head [
15].
There are strong clues that the brain serotonin and dopamine systems are closely interrelated. In a rat study, long-term treatment with SSRIs led to a significant reduction of tyrosine hydroxylase, an important enzyme in the biosynthesis of dopamine, in the substantia nigra and striatum [
16]. Furthermore, dopaminergic neurons contain serotonin receptors, and serotonergic neurons contain dopamine receptors [
16]. In an animal model for myoclonus dystonia, an inherited form of dystonia caused by a mutation in the epsilon-sarcoglycan gene (SCGE); the hypothesis of a dysbalanced dopamine-serotonin system has been confirmed. SCGE knockout mice show all the signs of dystonia, from jerks to depression-like behavior. After sacrificing, neurochemical studies in the striata of these mice showed increased levels of dopamine metabolites that correlated with motor performance (dystonia and jerks), while the level of serotonin metabolites, that was not significantly different from wild-type mice, inversely correlated with motor performance [
17]. Jerks in CD, that resemble myoclonus in myoclonus dystonia, may also be related to alterations of the serotonin system.
Our hypothesis was that CD is associated with reduced SERT binding, especially in CD patients with psychiatric symptoms. Because of the relation of both dopamine and serotonin metabolites and motor performance, including jerks, in SCGE knockout mice, we expected the balance between DAT and SERT binding to be different in CD patients with jerks compared to those without. We tested these hypotheses by imaging SERT in the diencephalon/midbrain and DAT in the striatum with [123I]fluoropropyl-carbomethoxy-3β(4-iodophenyltropane) (FP-CIT) SPECT.
Discussion
This study did not show significant differences in the diencephalon/midbrain SERT binding in patients with idiopathic CD compared to controls. However, we did find a trend (p = 0.05) towards decreased diencephalon/midbrain SERT BPND in CD patients with psychiatric comorbidity and in CD patients with a depression compared to those without. In this group, results failed to reach significance, likely due to the small number of CD patients with depression (n = 5). Furthermore, a significant correlation between the diencephalon/midbrain SERT and striatal DAT binding in CD patients with jerks was detected. This correlation was not present in controls and CD patients without jerks.
A trend towards reduced diencephalon/midbrain SERT BP
ND in CD patients with depression is consistent with results previously reported in patients with major depressive disorder, but without dystonia [
9]. Reduced SERT binding can be caused by reduced expression of SERTs on serotonergic neurons and/or increased occupancy of the SERT by high levels of endogenous synaptic serotonin. Considering that postmortem studies in major depression found reduced numbers of SERTs in the midbrain, the first theory seems more likely. Furthermore, PET studies in depression have also showed increased binding to serotonin 1
A receptors, both the postsynaptic receptors on target neurons throughout the brain as well as the presynaptic autoreceptors in the raphe nuclei. This is in both cases hypothesized to reflect increased number of receptors. The higher number of autoreceptors in the raphe nuclei results in a lower firing frequency and thus reduced synaptic release of serotonin [
31]. If this is also the case in patients with CD, this would explain the reduced level of serotonin metabolites that was found in cerebrospinal fluid of dystonia patients, and supports also our postulate that the currently observed lower SERT binding is not caused by an increased release of serotonin [
11]. It would be interesting to confirm this theory in a future study in CD with a selective serotonin 1
A receptor PET tracer such as [
11C]WAY-100635.
We found a statistically significant and positive correlation between striatal DAT and extrastriatal SERT BP
ND in CD patients with jerks, that was not present in patients without jerks. This might indicate that the relationship between SERT and DAT binding influences the motor phenotype of CD, more specifically whether a patient develops jerks or not. Recent studies in Parkinson’s disease (PD) have shown that the relative amount of DATs and SERTs can be imbalanced and lead to complications. After 5–10 years, patients with PD often develop levodopa-induced dyskinesias (LIDs), and these LIDs are associated with relatively intact serotonergic nerve terminals. PD patients with more available serotonin nerve terminals are more likely to develop LIDs [
32]. In agreement with this hypothesis, the striatal SERT/DAT ratio was higher in PD patients suffering from LID than without [
33]. In our patients with jerks, higher SERT BP
ND was related to higher DAT BP
ND which might indicate that CD patients with jerks also have more intact serotonergic nerve terminals. This hypothesis should be tested in future studies, as has been suggested for the development of LIDs in PD [
33].
This study has several limitations [
5]. We did not obtain data on disease duration. These data are difficult to obtain, as CD often starts with mild complaints and it can take months to years before the right diagnosis is made. Furthermore, psychiatric symptoms, which are now considered part of the phenotype, often precede motor symptoms, making it difficult to establish exactly the moment the disease started [
6]. Patients in our study were not allowed to use any dopaminergic or serotonergic medication that may influence [
123I]FP-CIT binding in vivo [
18]; however, they received BoNT injections and were allowed to use benzodiazepines. Furthermore, most subjects used medication for other conditions. Patients were scanned within a week of BoNT administration, making it unlikely that BoNT had an effect on SERT binding ratios. Also, no significant effect of benzodiazepines on [
123I]FP-CIT binding has been described. Patients in our study used a low dosage of oxazepam or clonazepam. We do not think this has influenced our results. [
123I]FP-CIT is metabolized by cytochrome P450 type 3A (CYP3A) in the liver, which metabolizes most drugs. Therefore, many drugs might influence [
123I]FP-CIT metabolism and possibly SERT binding (see
discussion in Booij and Kemp [
18]). The only potential influence we found was codeine, which was used by one of our patients in a low dose, making it unlikely this influenced our results. Furthermore, this subject had a SERT BP
ND of 0.23 which is around the group median.
The radiotracer we used is not a selective radiotracer for SERT. [
123I]FP-CIT binds both to striatal DAT and extrastriatal SERT, while, for example, [
123I]ADAM is highly SERT-selective. We chose to use [
123I]FP-CIT in this study so we could image both striatal DAT and extrastriatal SERT in one scanning session, limiting the number of visits and the exposure to radiation for our participants. Imaging the SERT in extrastriatal brain areas with [
123I]FP-CIT SPECT is well validated and done before by several groups in several different patient populations [
30,
34]. Moreover, in this study, extrastriatal SERT has been examined 2 h after bolus injection, which has been validated previously, and offers the advantage of relatively high count statistics [
23]. One factor to take into account is the small, but not negligible, number of serotonergic neurons, and consequently SERT, in the cerebellum, which was used as a reference region, and consequently, we feel it is unlikely that using the cerebellar binding to assess non-specific binding has significantly influenced our results.
SERTs are highly present in the diencephalon/midbrain but are also present in striatum. SERTs in the striatum are highly outnumbered by DATs making it impossible to measure SERT in the striatum with [123I]FP-CIT. In future studies, it may be of interest to use selective SERT tracers to evaluate whether our present observations on the diencephalon/midbrain SERT binding are also true for striatal SERT binding. Another limitation of this study is the significant number of scans that had to be excluded from the analysis. Taking this in regard, we still have the largest SPECT imaging study in patients with dystonia thus far, as well as the first study to investigate SERT binding in CD.